Overview
The PROTECTION® Trial Programme is a comprehensive international programme that consists of 10 trials examining the efficacy of Pritor®/Kinzalmono® as well as PritorPlus®/Kinzalkomb® at different stages of the cardiovascular and renal continuum in 6,875 patients with varying degrees of cardiovascular risk from 32 countries worldwide.
In order to test the clinical efficacy of Pritor®/Kinzal®, the main objective of the PROTECTION® Programme was to compare it to gold standards medications in at-risk patient populations.
